Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15808578rdf:typepubmed:Citationlld:pubmed
pubmed-article:15808578lifeskim:mentionsumls-concept:C0237798lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0450127lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0072980lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0085149lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0009429lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0205470lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:15808578lifeskim:mentionsumls-concept:C0556895lld:lifeskim
pubmed-article:15808578pubmed:issue1lld:pubmed
pubmed-article:15808578pubmed:dateCreated2005-4-5lld:pubmed
pubmed-article:15808578pubmed:abstractTextWe reported that a 60-day course of combination therapy with tacrolimus and sirolimus induced long-term survival of renal allograft after withdrawal of immunosuppressants in Vervet monkeys. In the present study, the mechanism of drug-induced allograft survival was evaluated via Th1/Th2 cytokines, apoptosis and MLC activity in primates. MATERIALS AND METHODS: Cytokines were evaluated by ELISA. MLR and CTL assays were performed by incorporation of 72 hours (3)H-TdR and 4 hours (51)Cr release assay. RESULTS: A 60-day course of tacrolimus with sirolimus resulted in long-term survival of kidney allografts. (67% > 100 days) without intermittent acute rejection. Low sensitivity to MLR was seen in long-term renal allograft survival among monkeys treated with tacrolimus and sirolimus. Increased levels of CD3(+)CD8(+), CD3(+)/CD56(+) NKT cells and CD86(+)CD8(-)CD11(+) dendritic cells were observed. A population of high expression of CD4(+)FasL(+) was detected. In addition, the concentrations of IL-2 and IFN-gamma from long-term allograft surviving monkeys was not significantly increased, rather a late phase dominance of Th2, IL-4, IL-10, and TGF-beta was found correlated with long-term survival of recipients. In conclusion, the mechanism of tacrolimus and sirolimus induced long-term allograft survival in primates relates to up-regulated FasL expression, NKT cells and dendritic cells, with downregulation of MLR sensitivity. It is also associated with late-dominant expression of Th2 cytokines.lld:pubmed
pubmed-article:15808578pubmed:languageenglld:pubmed
pubmed-article:15808578pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15808578pubmed:citationSubsetIMlld:pubmed
pubmed-article:15808578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15808578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15808578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15808578pubmed:statusMEDLINElld:pubmed
pubmed-article:15808578pubmed:issn0041-1345lld:pubmed
pubmed-article:15808578pubmed:authorpubmed-author:NGLLlld:pubmed
pubmed-article:15808578pubmed:authorpubmed-author:ChenHHlld:pubmed
pubmed-article:15808578pubmed:authorpubmed-author:DalozePPlld:pubmed
pubmed-article:15808578pubmed:authorpubmed-author:XuDDlld:pubmed
pubmed-article:15808578pubmed:authorpubmed-author:PyBBlld:pubmed
pubmed-article:15808578pubmed:issnTypePrintlld:pubmed
pubmed-article:15808578pubmed:volume37lld:pubmed
pubmed-article:15808578pubmed:ownerNLMlld:pubmed
pubmed-article:15808578pubmed:authorsCompleteYlld:pubmed
pubmed-article:15808578pubmed:pagination150-4lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:meshHeadingpubmed-meshheading:15808578...lld:pubmed
pubmed-article:15808578pubmed:articleTitleImmunological evaluation of combination therapy with tacrolimus and sirolimus on long-term allograft survival in nonhuman primates.lld:pubmed
pubmed-article:15808578pubmed:affiliationLaboratory of Experimental Surgery, Research Center of CHUM, Notre-Dame Hospital, University of Montreal, Montreal, Quebec, Canada H2L 2W5.lld:pubmed
pubmed-article:15808578pubmed:publicationTypeJournal Articlelld:pubmed